Recent Updates
Recently added Catalysts
FRNM Positive Sentiment

Freenome to Participate in the Piper Sandler 38th Annual Healthcare Conference

Key Takeaway: Freenome, Inc. will participate in the Piper Sandler 38th Annual Healthcare Conference on December 1, 2026. Management will engage in a fireside chat from 4:30 PM to 4:55 PM Eastern Time. The company specializes in AI-driven multiomics for early cancer detection and has developed FDA-approved tests for colorectal cancer.

Market Sentiment Analysis

POSITIVE FACTORS

  • Freenome will participate in a significant healthcare conference.
  • The company is focused on early cancer detection.
  • Freenome's AI-driven platform aims to improve cancer screening.

Full Press Release Details

BRISBANE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (NASDAQ: FRNM), a personalized cancer detection company using an AI-driven multiomics platform to develop and optimize single- and multi-cancer blood tests, today announced company management will participate in the Piper Sandler 38th Annual Healthcare Conference.
Management will participate in a fireside chat from 4:30pm to 4:55pm Eastern Time on Tuesday, Dec. 1, 2026.
A live and archived webcast of the events will be available on the “Events” section of the Freenome investor relations website at https://investors.freenome.com/news-events/events.
About Freenome
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary AI-driven multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of FDA-approved SimpleScreen CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional single- and multi-cancer indications is designed to increase cancer screening participation among millions of at-risk individuals.

Freenome Contacts:

Investor Relations Gilmartin Group LLC investor-relations@freenome.com

Media Contact Ryan Flinn The Grace Group ryan@gracegroup.us media@gracegroup.us

Frequently Asked Questions

When will Freenome participate in the conference?

Freenome will participate on December 1, 2026.

What is the focus of Freenome's technology?

Freenome focuses on early cancer detection using an AI-driven platform.

Where can I watch the conference webcast?

The webcast will be available on Freenome's investor relations website.

What types of cancer does Freenome test for?

Freenome develops tests for colorectal and lung cancer, among others.

Last updated: Nov 17, 2026